MiNK Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| MiNK Therapeutics, Inc. | INKT - NASDAQ |
$12.00-$14.00 | $12.00 | $12.04 | 3.33 million | 10/15/2021 |
| Evercore ISI, William Blair | ||||||
Co-Manager(s): B.Riley Securities, Baird
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-09-14 Terms Added 2021-10-12 | ||||||
MiNK Therapeutics, Inc. Quote & Chart - Click for current quote - INKT
IPO Boutique aggregates information on public companies and private companies, such as "INKT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About MiNK Therapeutics, Inc. (adapted from MiNK Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "INKT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.